Irreversible electroporation for locally advanced pancreatic cancer

Aim. To assess overall survival and recurrence-free period in patients with locally advanced pancreatic cancer who underwent irreversible electroporation of the tumor in combination with chemotherapy. Matherials and methods. It was performed a prospective analysis of overall survival in 23 patients who underwent irreversible electroporation of unresectable pancreatic cancer for the period from May 2012 to March 2017. Control group consisted of 35 patients with pancreatic cancer stage III who received standard chemotherapy alone. Results. Mean age of patients was 61 years (range 45–80). All procedures were successful. Fifteen patients had pancreatic head cancer, 8 – cancer of pancreatic body. Preoperative chemotherapy has been applied in 20 (86.9%) patients for 4 months prior to surgery on the average. Seventeen (73%) patients underwent chemotherapy after electroporation procedure. 90-day mortality was 4.3% (n = 1) in electroporation group. Surgery was followed by improved local recurrence-free survival (12 and 6 months, respectively, p = 0.01) and distant recurrence-free survival (15 and 8 months, respectively, p = 0.03). Overall survival was 18 and 11 months, respectively (p = 0.03). Conclusion. Irreversible electroporation of locally advanced pancreatic cancer is safe. Four-month chemotherapy followed by surgical procedure is associated with good local response and better overall survival compared with chemotherapy alone. These data will be validated in further multicenter study.

pancreas, irreversible electroporation, combined treatment, nano-knife, minimally invasive surgery, pancreatic cancer

1. Oncologiia. Klinicheskie rekomendatsii [Oncology. Clinical guidelines]. Pod red. M.I. Davidova. Moscow: RONTs, 2015. 680 p. (In Russian)

2. Davydov M.I., Aksel' E.M. Malignant neoplasm statistics in 2014. Evrazijskij onkologicheskij zhurnal. 2016; 4: 692–879. (In Russian)

3. Chin V., Nagrial A., Sjoquist K., O'Connor C.A., Chantrill L., Biankin A.V., Scholten R.J., Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst. Rev. 2018; 3: CD011044. DOI: 10.1002/14651858.CD011044.pub2.

4. Sahay A., Sahay N., Kapoor A., Kapoor J., Chatterjee A. Percutaneous image-guided radiofrequency ablation of tumors in inoperable patients – immediate complications and overall safety. Indian J. Palliat. Care. 2016; 22 (1): 67–73. DOI: 10.4103/0973-1075.173951.

5. Marsanic P., Mellano A., Sottile A., De Simone M. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma. Med. Biol. Eng. Comput. 2017; 55 (7): 1123–1127. DOI: 10.1007/s11517-016-1603-9.

6. Martin R.C. 2nd, Kwon D., Chalikonda S., Sellers M., Kotz E., Scoggins C., McMasters K.M., Watkins K. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann. Surg. 2015; 262 (3): 486–494; discussion 492–494. DOI: 10.1097/SLA.0000000000001441.

7. Martin R.C. 2nd, McFarland K., Ellis S., Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J. Am. Coll. Surg. 2012; 215 (3): 361–369. DOI: 10.1016/j.jamcollsurg.2012.05.021.

8. Panchenkov D.N., Ivanov Yu.V., Pikunov D.Yu., Zabozlaev F.G., Nechunayev A.A., Kochieva M.P., Aleksanyan G.B. Irreversible electroporation of colorectal liver metastases with the “NANOKNIFE” system. Klinicheskaja praktika. 2013; 13 (1): 37–42. (In Russian)

9. Panchenkov D.N., Ivanov Yu.V., Soloviev N.A., Astakhov D.A., Nechunayev A.A. Irreversible electroporation with “NanoKnife” in managenment of pancreatic cancer (clinical case). Annaly khirurgicheskoy gepatologii = Annals of HPB surgery. 2014; 19 (1): 50–54. (In Russian)

10. Tarek M. Membrane electroporation: A molecular dynamics simulation. Biophys J. 2005; 88 (6): 4045–4053. DOI: 10.1529/biophysj.104.050617.

11. Meaking W.S., Edgerton J., Wharton C.W., Meldrum R.A. Electroporation induced damage in mammalian cell DNA. Biochim. Biophys. Acta. 1995; 1264 (3): 357–362. DOI: 10.1016/0167-4781(95)00177-8.

12. Beebe S.J., Blackmore P.F., White J., Joshi R.P., Schoenbach K.H. Nanosecond pulsed electric fields modulate cell function through intracellular signal transduction mechanisms. Physiol. Meas. 2004; 25 (4): 1077–1093.

13. Atlas po klassifikacii stadij zlokachestvennyh opuholej: pril. k 7-mu izd. Rukovodstva po (TNM) klassifikacii stadij zlokachestvennyh opuholej i Spravochnika AJCC [Atlas of the classification of stages of malignant tumors: adj. 7th ed. “Guidelines for the (TNM) classification of stages of malignant tumors” and “Handbook” AJCC] per. s angl. Pod red. A.D. Kaprina, A.H. Trahtenberga. 2-e izd. Moscow: Prakticheskaja medicina, 2014. 649 p. (In Russian)

14. Charlson M.E., Pompei P., Ales K.L., McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987; 40 (5): 373–383.

15. Iacobuzio-Donahue C.A., Fu B., Yachida S., Luo M., Abe H., Henderson C.M., Vilardell F., Wang Z., Keller J.W., Banerjee P., Herman J.M., Cameron J.L., Yeo C.J., Halushka M.K., Eshleman J.R., Raben M., Klein A.P., Hruban R.H., Hidalgo M., Laheru D. DPC4 gene status of the primarycarcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 2009; 27 (11): 1806–1813. DOI: 10.1200/JCO.2008.17.7188.

16. Bhutiani N., Agle S., Li Y., Li S., Martin R.C. 2nd. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J. Surg. Oncol. 2016; 114 (2): 181–186. DOI: 10.1002/jso.24288.